Schering AG remains on the European priority list of analysts at brokers Goldman Sachs, and has for some time had a positive recommendation. The granting of a US patent at the end of 1994 on methods to express interferon genes in Chinese hamster ovary cells has been another positive for the company, say the analysts.
It strengthens its global patented interferon franchise and increases the likelihood of favorable negotiations with US firm Biogen, a key competitor, whose manufacturing process may infringe Schering's patent.
Over a two-day period last week, the company's share price advanced around 62 Deutschemarks ($40) to 1,070 marks (see also pages 8 and 9). The analysts expect long-term sales growth of 7%-8% for the company, and are forecasting compound growth in earning per share of 25%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze